Literature DB >> 7113255

Metabolism of the new antihypertensive agent pinacidil in rat, dog and man.

E Eilertsen, M P Magnussen, H J Petersen, N Rastrup-Andersen, H Sørensen, E Arrigoni-Martelli.   

Abstract

1. The antihypertensive agent pinacidil is eliminated from the body mainly by biotransformation in the liver, followed principally by renal excretion of the metabolites. 2. The metabolism and elimination of pinacidil is similar in rat, dog and man, and is independent of the route of administration. 3. After an oral dose, the 24 h urinary excretion of unchanged pinacidil is 13, 4, and 5% in rat, dog and man, respectively. Faecal excretion in the rat and dog is 2 and 4%. 4. In rat, dog and man the main biotransformation product is the pyridine-N-oxide of pinacidil. Following oral administration of pinacidil, 40, 54 and 54%, respectively, is excreted in the urine as the N-oxide during the first 24 h, and less than 1% in the faeces in rat and dog. 5. Three unidentified minor metabolites were found in plasma, urine and faeces in rat and dog. 6. The major metabolite, the pyridine-N-oxide of pinacidil, has an anti-hypertensive potency about a quarter of that of pinacidil. In animals and human volunteers with normal kidney function, however, the plasma concn. of the N-oxide are always lower than those of the parent compound, so that the metabolite contributes little to the antihypertensive effect of pinacidil.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7113255     DOI: 10.3109/00498258209046793

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  12 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 2.  Pinacidil. Preclinical investigations.

Authors:  I Ahnfelt-Rønne
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Smooth muscle K+ channel openers; their pharmacology and clinical potential.

Authors:  A H Weston
Journal:  Pflugers Arch       Date:  1989       Impact factor: 3.657

4.  Variable metabolism of pinacidil: lack of correlation with the debrisoquine and trimethylamine C- and N-oxidative polymorphisms.

Authors:  R Ayesh; M Al-Waiz; A McBurney; S C Mitchell; J R Idle; J W Ward; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

5.  Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.

Authors:  A McBurney; P R Farrow; S Ainsworth; J W Ward
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

6.  Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.

Authors:  P Girard; J L Saumet; F Dubois; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.

Authors:  E G Breen; D Mulhall; J A Keogh
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Arterial vasodilating profile and biological effects of pinacidil in healthy volunteers.

Authors:  C Thuillez; E Pussard; E Bellissant; C Richer; R Kechrid; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

9.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Accumulation of pinacidil N-oxide during chronic treatment with pinacidil.

Authors:  A McBurney; J A Henry; J W Ward
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.